How long should tamoxifen be held before an elective surgery?

Holding Tamoxifen Before Elective Surgery

Hold tamoxifen for 14-28 days (1-2 half-lives) before elective surgery, particularly for procedures involving free flap reconstruction or prolonged immobilization.

Rationale and Evidence

The recommendation to hold tamoxifen perioperatively is based on its thrombotic risk profile and specific complications in reconstructive procedures. Tamoxifen has a long elimination half-life of approximately 7-14 days, requiring adequate washout time to minimize perioperative risks 1.

Key Surgical Considerations

For breast reconstruction procedures:

• Patients taking tamoxifen at the time of operation have significantly higher rates of complete flap loss compared to those not on hormone modulators (p < 0.001) 1
• Both tamoxifen and aromatase inhibitors increase donor site complication rates (p = 0.0021 and p < 0.0001, respectively) 1
• Evidence supports holding tamoxifen for 14-28 days preoperatively to mitigate these risks 1

For procedures with high VTE risk:

• Tamoxifen increases venous thromboembolism (VTE) risk, which is further amplified during surgical procedures requiring prolonged immobilization 2
• The FDA label confirms elevated thromboembolic events in tamoxifen-treated patients (1.7% vs 0.4% in placebo through 5 years) 3

Practical Algorithm

Determine holding period based on:

1. Surgery type: Free flap reconstruction or high-risk procedures → 14-28 days preoperatively
2. Standard elective procedures with moderate VTE risk → 14 days minimum
3. Low-risk minor procedures → May consider shorter duration (7-14 days)

Aromatase inhibitors require shorter holding:

• Hold for only 2-4 days preoperatively due to shorter half-life 1

Important Caveats

• One large study of 1,347 flaps found that withholding tamoxifen for 2 weeks before surgery successfully mitigated thrombotic risk, with no significant differences in complications compared to non-users 4
• However, the systematic review evidence more strongly supports the 14-28 day window for optimal risk reduction, particularly for flap loss 1
• Recent expert consensus (2026) indicates that for most breast reconstruction procedures, tamoxifen may not need to be held routinely, though this conflicts with earlier systematic review data 5

Oncologic Safety

Temporary discontinuation is safe:

• The FDA label and ASCO guidelines focus on long-term duration (5-10 years total) but do not contraindicate brief perioperative interruptions 6, 3
• A 2-4 week interruption in a multi-year treatment course has negligible impact on overall cancer outcomes
• Resume tamoxifen postoperatively once adequate wound healing is achieved and VTE risk normalizes (typically 1-2 weeks post-surgery)

The balance favors holding tamoxifen given the significant increase in surgical complications (particularly flap loss) versus the minimal oncologic impact of brief interruption in long-term adjuvant therapy.